A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy, Safety, and Immunogenicity of GR1802 in Participants With Chronic Rhinosinusitis With Nasal Polyps
Latest Information Update: 26 Jul 2024
At a glance
- Drugs Telikibart (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Therapeutic Use
- Sponsors Genrix (Shanghai) Biopharmaceuticals
Most Recent Events
- 26 Jul 2024 New trial record